The problem: Early ARV treatment in Sub-Saharan Africa reaches only approximately 50% of infants born with HIV (CLHIV)).1 Mortality in infants in the first 12 months after diagnosis is still over 10% in early treated infants diagnosed at birth, 25% in infants diagnosed with opportunistic infections. According with our experience, the probability of virological control 1 year after diagnosis is only 25 to 35%, even after roll-out of DTG. The proposed solution: Four shots of subcutaneous (SC), long-half-life broadly neutralizing antibodies (bNAbs) at diagnosis, and 3, 6 and 9 months after diagnosis, as an add-on to standard oral ART will provide immediate therapeutic benefit and decrease HIV viral load levels in the most critical period of life of CLHIV, allowing for a decreased risk of co-infections, HIV-encephalopathy and death. The pathway A collaborative framework between a scientific network with partners in several SSA countries, producers of bNAbs, and European and African laboratories. The impact: Increase the probability of viral suppression 1 year after diagnosis from 30% to 95% to achieve 2030 UNAIDS 3rd target. Reduction of HIV- associated morbidity and mortality in the first year of life and beyond.